Skip to main content

Advertisement

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes

Fig. 4

Association between 8-month autoantibody profile and initial drug-free remission (DFR) in patients seropositive for anti-citrullinated protein 2 (anti-CCP2) IgG, rheumatoid factor (RF) IgM, or anti-carbamylated protein (anti-CarP) IgG at baseline, who had serum available for re-measurement at 8 months (n = 103). Pairwise comparisons between each group were not significant after multiple testing (see text). a Percentage of patients with the specified number of isotypes present reaching initial DFR. The composite number of isotypes consists of the positivity count for anti-CCP2 IgG, IgM, IgA; RF IgM, IgA; and anti-CarP IgG, IgM, IgA. Due to some seropositive patients testing negative upon re-measurement or seroconverting to negative by 8 months, the total number of patients with any isotypes present was 92. b Percentage of patients with the specified number of anti-modified protein antibodies (AMPAs) present reaching initial DFR. The composite number of AMPAs consists of the positivity count for anti-CCP2 IgG, anti-CarP IgG, anti-citrullinated-vimentin 59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG and α 27-43 IgG, anti-citrullinated-enolase 5-20 IgG, anti-acetylated-lysine IgG, and anti-acetylated-ornithine IgG. Thirteen patients were RF IgM positive but had no AMPA antibodies or had seroconverted to negative by 8 months (not shown). c Percentage of patients with the specified number of antibodies present reaching initial DFR. Anti-cit. pept. Abs, anti-citrullinated peptide antibodies; Anti-acetyl. pept. Abs, anti-acetylated peptide antibodies. Reported p values are adjusted for multiple testing using Holmes-Bonferroni methods. ns, not significant (p ≥ 0.05); *p < 0.05; **p < 0.01, ***p < 0.001

Back to article page